Summary of grade 3 or higher treatment-emergent adverse events according to CTCAE version 5.0
| AEs regardless of attribution . | Grade 3 . | Grade 4 . |
|---|---|---|
| Acute kidney injury | — | 1 (5) |
| Alanine aminotransferase increased | 3 (14) | — |
| Anorexia | 1 (5) | — |
| Aspartate aminotransferase increased | 2 (9) | — |
| Bone pain | 1 (5) | — |
| Depression | 1 (5) | — |
| Diarrhea | 3 (14) | — |
| Disease progression | 2 (9) | — |
| Esophageal pain | 1 (5) | — |
| Fatigue | 1 (5) | — |
| Febrile neutropenia | 2 (9) | — |
| Hematuria | 1 (5) | — |
| Hyperglycemia | 1 (5) | — |
| Mucositis oral | 2 (9) | — |
| Neutrophil count decreased | 2 (9) | 4 (18) |
| Platelet count decreased | 6 (27) | 3 (14) |
| Pleural effusion | 1 (5) | — |
| Rash maculo-papular | 4 (18) | — |
| Sepsis | — | 1 (5) |
| Vascular access complication | 2 (9) | — |
| White blood cell decreased | 1 (5) | 4 (18) |
| AEs regardless of attribution . | Grade 3 . | Grade 4 . |
|---|---|---|
| Acute kidney injury | — | 1 (5) |
| Alanine aminotransferase increased | 3 (14) | — |
| Anorexia | 1 (5) | — |
| Aspartate aminotransferase increased | 2 (9) | — |
| Bone pain | 1 (5) | — |
| Depression | 1 (5) | — |
| Diarrhea | 3 (14) | — |
| Disease progression | 2 (9) | — |
| Esophageal pain | 1 (5) | — |
| Fatigue | 1 (5) | — |
| Febrile neutropenia | 2 (9) | — |
| Hematuria | 1 (5) | — |
| Hyperglycemia | 1 (5) | — |
| Mucositis oral | 2 (9) | — |
| Neutrophil count decreased | 2 (9) | 4 (18) |
| Platelet count decreased | 6 (27) | 3 (14) |
| Pleural effusion | 1 (5) | — |
| Rash maculo-papular | 4 (18) | — |
| Sepsis | — | 1 (5) |
| Vascular access complication | 2 (9) | — |
| White blood cell decreased | 1 (5) | 4 (18) |
Data are expressed as N (%). CTCAE, Common Toxicity Criteria for Adverse Events.